These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33184101)

  • 1. The optimal treatment of stage I nonsmall cell lung cancer in the era of SABR and modern day lung resections.
    Vallieres E
    Eur Respir J; 2020 Nov; 56(5):. PubMed ID: 33184101
    [No Abstract]   [Full Text] [Related]  

  • 2. Surgical and nonsurgical approaches to small-size nonsmall cell lung cancer.
    De Ruysscher D; Nakagawa K; Asamura H
    Eur Respir J; 2014 Aug; 44(2):483-94. PubMed ID: 24925923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
    Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M
    Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer.
    Palma D; Senan S
    Curr Opin Oncol; 2011 Mar; 23(2):133-9. PubMed ID: 21107257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To SABR or not to SABR? Indications and contraindications for stereotactic ablative radiotherapy in the treatment of early-stage, oligometastatic, or oligoprogressive non-small cell lung cancer.
    Shultz DB; Diehn M; Loo BW
    Semin Radiat Oncol; 2015 Apr; 25(2):78-86. PubMed ID: 25771411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lobectomy should remain the first choice for treating early stage nonsmall cell lung cancer.
    Deng HY; Zhou Q
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31273034
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults.
    Smith BD; Jiang J; Chang JY; Welsh J; Likhacheva A; Buchholz TA; Swisher SG; Shirvani SM
    J Geriatr Oncol; 2015 Jul; 6(4):324-31. PubMed ID: 26094172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Stage I Lung Cancer with Stereotactic Ablative Radiation Therapy.
    Dan T; Williams NL
    Surg Oncol Clin N Am; 2017 Jul; 26(3):393-403. PubMed ID: 28576179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SABR-COMET: harbinger of a new cancer treatment paradigm.
    Loo BW; Diehn M
    Lancet; 2019 May; 393(10185):2013-2014. PubMed ID: 30982688
    [No Abstract]   [Full Text] [Related]  

  • 10. Technical Note: Dosimetric evaluation of Monte Carlo algorithm in iPlan for stereotactic ablative body radiotherapy (SABR) for lung cancer patients using RTOG 0813 parameters.
    Pokhrel D; Badkul R; Jiang H; Kumar P; Wang F
    J Appl Clin Med Phys; 2015 Jan; 16(1):5058. PubMed ID: 25679161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAbR as an Alternative Boost Modality for Cervical Cancer: A Cautionary Exercise.
    Kamrava M; Chino JP; Beriwal S
    Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):472-474. PubMed ID: 32014146
    [No Abstract]   [Full Text] [Related]  

  • 12. CyberKnife stereotactic ablative radiotherapy for lung tumors.
    Gibbs IC; Loo BW
    Technol Cancer Res Treat; 2010 Dec; 9(6):589-96. PubMed ID: 21070081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
    Kashihara T
    Lancet Oncol; 2021 Dec; 22(12):e534. PubMed ID: 34856144
    [No Abstract]   [Full Text] [Related]  

  • 14. SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
    Zhang J; Liu L; Zhao K; Guo C; Li S
    Lancet Oncol; 2021 Dec; 22(12):e536. PubMed ID: 34856146
    [No Abstract]   [Full Text] [Related]  

  • 15. SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
    Luo MS
    Lancet Oncol; 2021 Dec; 22(12):e535. PubMed ID: 34856145
    [No Abstract]   [Full Text] [Related]  

  • 16. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.
    Iyengar P; Westover K; Timmerman RD
    Semin Respir Crit Care Med; 2013 Dec; 34(6):845-54. PubMed ID: 24258574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).
    Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R
    Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SABR versus conventional fractionation regimens in NSCLC.
    Joseph N; Choudhury A
    Lancet Oncol; 2019 May; 20(5):e231. PubMed ID: 31044708
    [No Abstract]   [Full Text] [Related]  

  • 20. SABR versus conventional fractionation regimens in NSCLC.
    Addeo A; Buffoni L
    Lancet Oncol; 2019 May; 20(5):e230. PubMed ID: 31044707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.